Daiichi Gets Into Generics With Stake In Ranbaxy
Executive Summary
Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the In Vivo blog. Visit the blog at http://invivoblog.blogspot.com/.
You may also be interested in...
Ranbaxy’s Ripples: Generic Drug Integrity Returns As Focus For Congress, FDA
Problems at a drug company have once again put FDA in the crosshairs of the House Energy and Commerce Committee
Ranbaxy’s Ripples: Generic Drug Integrity Returns As Focus For Congress, FDA
Problems at a drug company have once again put FDA in the crosshairs of the House Energy and Commerce Committee
“Bio-buck” Deals A Good Risk-Sharing Strategy, Pharma Execs Say At BIO
Bio-buck deals, those back-end-loaded, early-stage collaborations that grab headlines because of the big dollars promised, are a win-win risk share, big pharma execs say